Not really out flanked... More like over react. This is classic over reaction and I am buying all I can of this and the celg and BIIB being dragged down with it. The estimate is that the express scripts deal will result in GILD losing only about 5% market share to ABBV in the hep market for this drug. They will still have over 50 or 60% market share. To me the 20% sell off doesn't add up to the above outline. This company was still relatively cheap at 105+. At 90 it's absurdly cheap. People wanted their chance to buy these companies at 20% under their 52 week highs... Here's your chance. They'll all rebound in January imo
News 
Market Data 
Discover 
